 | Up a level |
Passweg, J R; Labopin, M; Christopeit, M; Cornelissen, J; Pabst, Thomas; Socié, G; Russel, N; Yakoub-Agha, I; Blaise, D; Gedde-Dahl, T; Labussière-Wallet, H; Malladi, R; Forcade, E; Maury, S; Polge, E; Lanza, F; Gorin, N C; Mohty, M; Nagler, A (2020). Post remission consolidation by autologous HCT for AML in CR1, negative implications for subsequent allogeneic HCT in CR2. A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Biology of blood and marrow transplantation, 26(4), pp. 659-664. Elsevier 10.1016/j.bbmt.2019.11.021
Versluis, J; In 't Hout, F E M; Devillier, R; van Putten, W L J; Manz, M G; Vekemans, M-C; Legdeur, M-C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J M; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, Thomas; Willemze, R; Löwenberg, B; Ossenkoppele, G; ... (2017). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1), pp. 26-33. Nature Publishing Group 10.1038/leu.2016.183
